Actinium Pharmaceuticals, Inc (ATNM) Dividend History

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted cancer therapies using its proprietary Antibody-Radionuclide Conjugate (ARC) platform. The company specializes in creating treatments for hematologic malignancies and other cancers, leveraging its expertise in radiolabeled antibody technology to deliver targeted radiation directly to cancer cells.

Dividend History

Actinium Pharmaceuticals, Inc currently does not pay dividends

Company News

המועד האחרון לתביעה נגד ATNM: רוזן, משרד עורכי דין ידוע מאוד, מעודד את משקיעי Actinium Pharmaceuticals, Inc שצברו הפסדים של יותר מ- 100 אלף דולר, להבטיח ייעוץ לפני המועד האחרון החשוב של 27 במאי בתביעה ייצוגית בניירות ערך – ATNM

Rosen Law Firm is encouraging investors in Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to seek legal counsel before the May 27 deadline for a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about the likelihood of its Iomab-B drug candidate being approved by the FDA.

GlobeNewswire Inc.
ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNM

Rosen Law Firm is encouraging investors of Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to secure legal counsel before the May 27, 2025 deadline for a securities class action lawsuit.

GlobeNewswire Inc.
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making materially false and misleading statements about the likelihood of FDA approval for its drug Iomab-B.

GlobeNewswire Inc.
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit

Actinium Pharmaceuticals, Inc. (ATNM) is facing a class action lawsuit due to alleged misleading statements about its lead product candidate, lomab-B, and its planned Biologics License Application (BLA) filing. The lawsuit alleges that the company misled investors about the likelihood of the BLA being accepted and approved by the FDA.

GlobeNewswire Inc.
ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making false and/or misleading statements about its Iomab-B Biologics License Application, which the FDA is unlikely to accept or approve.

GlobeNewswire Inc.

Featured Companies: BITF TFX

Dividend data last updated 06/07/2025 20:36:18 UTC